Status:
COMPLETED
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
Bioequivalence of an empagliflozin/metformin (FDC) tablet compared with single tablets of two strength of empagliflozin and metformin (Part I) under fasted and under fed conditions and bioequivalence ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 1\. Healthy male and female subjects
- Exclusion criteria:
- 1\. Any relevant deviation from healthy conditions
Exclusion
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01811953
Start Date
March 1 2013
End Date
May 1 2013
Last Update
July 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1276.8.1 Boehringer Ingelheim Investigational Site
Biberach, Germany